Volume : 08, Issue : 09, September – 2021
Title:
24.A PROSPECTIVE OBSERVATIONAL STUDY ON EFFICACY OF HEPATOPROTECTIVE DRUGS IN IN-PATIENTS WITH ALCOHOLIC LIVER DISEASE IN A TERTIARY CARE TEACHING HOSPITAL
Authors :
Mohammed Majid Iqbal*, Sameer Raza Faisal , Muhammad Hasan Shareef and Mohammed Irfan
Abstract :
Abstract:
Aims and objectives: The study was carried out with an aim to evaluate the efficacy of the hepatoprotective drugs prescribed to the patients. This might help in designing better treatment plans for the patients suffering from the alcoholic liver disease. The dose effectiveness can be analysed for appropriate dosing frequency of the prescribed drugs for better treatment plan and improving the quality of life and providing better health care to the society.
Methodology: The study was carried out in a tertiary care teaching hospital on 100 subjects admitted in the hospital (in-patients). The study was carried out for a period of 6 months. During this period, different patients suffering from the alcoholic liver disease were identified and their disease conditions were monitored and the levels of aspartate transaminase, alanine transaminase and serum bilirubin levels were checked after repeated dosing of the drugs during the course of treatment.
Results: The patients were divider based on gender, age, duration of intake of alcohol and the type of alcoholic liver disease they suffer from. It was seen that the males are more prone to the disease than female due to increased alcohol consumption. Binge alcohol intake for more than 5-10 years can cause serious damages to the liver. After repeated drug administration, the blood levels for Aspartate transaminase and Alanine transaminase and serum bilirubin were checked and it was noted that there was a significant improvement in the levels of these enzymes in the blood when both Rifaximin and Ursodeoxycholic acid were administered in combined form at a dose of 550mg and 300mg respectively.
Conclusion: In our study we conclude that the extent of damage caused to the liver due to alcohol consumption can be controlled and further damage can be prevented by providing appropriate treatment measures using drugs and other preventive measures along with strict abstinence of alcohol.
Keywords: Alcoholic Liver Disease, Rifaximin, Ursodeoxycholic acid
Cite This Article:
Please cite this article in press Mohammed Majid Iqbal et al, A Prospective Observational Study On Efficacy Of Hepatoprotective Drugs In In-Patients With Alcoholic Liver Disease In A Tertiary Care Teaching Hospital
., Indo Am. J. P. Sci, 2021; 08(9).
Number of Downloads : 10
References:
1. Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston; Davidson’s principles and practices of internal medicine, 21st edition, page no 954-956.
2. Roger Walker and Cate Whittlesea; Clinical pharmacy and pharmacotherapeutics, 5th edition, page no 238.
3. Cara Torruellas, Samuel W French and Valentina Medici. Diagnosis of Alcoholic liver disease 2014
4. Ina Bergheim, Craig J. McClain and Gavin E. Arteel. Treatment of alcoholic liver disease, 2009
5. Ursodeoxycholic acid in chronic liver disease. (Gutgut.bmj.com)
6. Ursodeoxycholic acid – DrugBank (www.drugbank.ca)
7. Behnam Saberi, Alia S. Dadabhai and Esteban Mezey. Current management of alcoholic hepatitis and future therapies, 2016.
8. Jiannis Vlachogiannakos. Et al. Journal of Gastroenterology and Hepatology, vol 28 issue 3. 2016
9. A Puxeddu, M Quartini, A Massimetti, A Ferrieri. Rifaximin in treatment of chronic hepatic encephalopathy, current medical research and opinion 13, 247-281.
10. KD Mullen and William P Forbes. Clinical gastroenterology and hepatology vol 12 Issue 8 pgno: 1390-1397.
11. Leon A Adams,Claudia O Zein, et al, A Pilopt trial of pentoxifyllinin alcoholic steatohepatitis, The American journal of gastroenterology page 99(2012).
12. JN Plevris, PC Hayes, John Pelvris. European Journal of gastroenterology and hepatology vol 3 issue 9 pgno: 653-656
13. Jerold A Cohen MD and Marshal A Kaplan MD; Digestive disease and sciences; The SGOT/SGPT ratio- an indicator of alcoholic liver disease, page 24.
14. Paul Angulo. Current gastroenterology report 2002 vol 1 issue 4 pgno: 37-44’
15. Evangelos Akriviadis et al. American gastroenterological association 2000 article no : 119 pgno: 1637-1648
16. Radan Bruha, Karel Dvorak and Jaromir Petrtyl. World journal of hepatology-alcoholic liver disease 2012 pgno: 81-90
17. What’s to know about alcoholic liver disease? Medically reviewed by Judith Marcin, M.D. on February 6, 2018 (https://www.medicalnewstoday.com/articles/215638.php)
18. Gilles Pelletier et al, A Randomized Controlled Trial of Ursodeoxycholic Acid in Patients With Alcohol-Induced Cirrhosis and Jaundice.
19. Tessa M. Cacciottolo, Arjun Kingdon, Graeme J. Alexander Clinical Gastroenterology and Hepatology, Volume 12, Issue 10, October 2014, Pages 1765
20. Trainer and graziadei; Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
21. O. Lukivskava, E. Naruta, N. Prokopchik, V. Buko; Hepatoprotective action of UDCA in alcoholic fatty liver.